Related Experiment Video
Updated: Feb 13, 2026

Multi-Tracer Studies of Brain Oxygen and Glucose Metabolism Using a Time-of-Flight Positron Emission Tomography-Computed Tomography Scanner
Published on: June 7, 2024
Positron emission tomography of sodium glucose cotransport activity in high grade astrocytomas
Vladimir Kepe1,2, Claudio Scafoglio1,3, Jie Liu1
1Department of Molecular and Medical Pharmacology, The Geffen School of Medicine at UCLA, Los Angeles, CA, 90095, USA.
Abstract:
A novel glucose transporter, the sodium glucose cotransporter 2 (SGLT2), has been demonstrated to contribute to the demand for glucose by pancreatic and prostate tumors, and its functional activity has been imaged using a SGLT specific PET imaging probe, α-methyl-4-[F-18]fluoro-4-deoxy-D-glucopyaranoside (Me-4FDG). In this study, Me-4FDG PET was extended to evaluate patients with high-grade astrocytic tumors. Me-4FDG PET scans were performed in four patients diagnosed with WHO Grade III or IV astrocytomas and control subjects, and compared with 2-deoxy-2-[F-18]fluoro-D-glucose (2-FDG) PET and magnetic resonance imaging (MRI) of the same subjects. Immunocytochemistry was carried out on Grade IV astrocytomas to determine the cellular location of SGLT proteins within the tumors. Me-4FDG retention was pronounced in astrocytomas in dramatic contrast to the lack of uptake into the normal brain, resulting in a high signal-to-noise ratio. Macroscopically, the distribution of Me-4FDG within the tumors overlapped with that of 2-FDG uptake and tumor definition using contrast-enhanced MRI images. Microscopically, the SGLT2 protein was found to be expressed in neoplastic glioblastoma cells and endothelial cells of the proliferating microvasculature. This preliminary study shows that Me-4FDG is a highly sensitive probe for visualization of high-grade astrocytomas by PET. The distribution of Me-4FDG within tumors overlapped that for 2-FDG, but the absence of background brain Me-4FDG resulted in superior imaging sensitivity. Furthermore, the presence of SGLT2 protein in astrocytoma cells and the proliferating microvasculature may offer a novel therapy using the SGLT2 inhibitors already approved by the FDA to treat type 2 diabetes mellitus.
Insights
New PET imaging using Me-4FDG effectively visualizes high-grade astrocytomas by targeting sodium glucose cotransporter 2 (SGLT2). This offers superior sensitivity compared to standard 2-FDG PET for brain tumor detection.
Area of Science:
- Oncology
- Nuclear Medicine
- Neuroscience
Background:
- Sodium glucose cotransporter 2 (SGLT2) is implicated in glucose uptake by certain tumors.
- Previous studies utilized SGLT-specific probes for imaging pancreatic and prostate tumors.
- High-grade astrocytomas (WHO Grade III-IV) require improved diagnostic imaging modalities.
Purpose of the Study:
- To evaluate the utility of Me-4FDG PET for visualizing high-grade astrocytomas.
- To compare Me-4FDG PET imaging with 2-FDG PET and MRI in astrocytoma patients.
- To investigate the expression and cellular localization of SGLT2 in astrocytomas.
Main Methods:
- Me-4FDG PET scans were performed on four patients with WHO Grade III or IV astrocytomas and control subjects.
- Comparative analysis with 2-FDG PET and contrast-enhanced MRI was conducted.
- Immunocytochemistry was used to determine SGLT protein expression in Grade IV astrocytomas.
Main Results:
- Me-4FDG PET demonstrated pronounced retention in astrocytomas with minimal uptake in normal brain tissue, yielding a high signal-to-noise ratio.
- Macroscopic distribution of Me-4FDG overlapped with 2-FDG uptake and contrast-enhanced MRI tumor definition.
- Microscopic analysis revealed SGLT2 protein expression in neoplastic glioblastoma cells and tumor-associated endothelial cells.
Conclusions:
- Me-4FDG PET is a highly sensitive imaging probe for visualizing high-grade astrocytomas.
- Me-4FDG PET offers superior imaging sensitivity over 2-FDG PET due to the absence of background brain uptake.
- SGLT2 expression in astrocytomas suggests potential for novel targeted therapies using SGLT2 inhibitors.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
10:20Automation of a Positron-emission Tomography PET Radiotracer Synthesis Protocol for Clinical Production
Published on: October 26, 2018
Related Concept Videos
Positron Emission Tomography
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
Imaging Studies II: Positron Emission Tomography and Scintigraphy
Fundamental Principles of PET
Secondary Active Transport
Emission Spectra
Graded Potential
Graded potentials fall into two categories: depolarizing and hyperpolarizing. Depolarizing graded potentials typically occur when sodium (Na+) or...
Glucose Homeostasis: Regulation of Blood Glucose
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...